Phosphodiesterase type 5 and high altitude pulmonary hypertension.

  title={Phosphodiesterase type 5 and high altitude pulmonary hypertension.},
  author={Almaz A. Aldashev and Baktybek Kojonazarov and Toktosun A. Amatov and Talant M. Sooronbaev and Mirsaid M. Mirrakhimov and Nicholas W Morrell and John Wharton and Martin R Wilkins},
  volume={60 8},
BACKGROUND This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). METHODS 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac catheterisation and 29 (66%) had a resting mean pulmonary artery pressure (PAP) above 25 mmHg. 22… CONTINUE READING
33 Extracted Citations
28 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 33 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 28 references

Similar Papers

Loading similar papers…